1 / 24

Pharmaceutical Case Competition 2007

Pharmaceutical Case Competition 2007. HLM Biotech Consulting. Paul Di Capua, MD, MBA candidate Robert Stavert, MD, MBA candidate Adrian Garcia, MBA candidate. November 30, 2007. Pharmaceutical pipeline is drying up Diversification of drug portfolio into biologics Potential synergies.

barny
Download Presentation

Pharmaceutical Case Competition 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceutical Case Competition 2007 HLM Biotech Consulting Paul Di Capua, MD, MBA candidate Robert Stavert, MD, MBA candidate Adrian Garcia, MBA candidate November 30, 2007

  2. Pharmaceutical pipeline is drying up Diversification of drug portfolio into biologics Potential synergies WHY BIOTECH ? WHY NOW? Cash reserves Slim pipeline Blockbusters are going off-patent Sucessfulbiotech with proven track record Growth of MS market Potential synergies So competition doesn’t acquire Biogen

  3. “When we look back, this will seem a very expensive time.” – Tony Robinson, Head of Business Development and Licensing at Novartis Buyers beware!

  4. Multiple Sclerosis: Pathogenesis and mechanisms of therapy Figure from: Compston A, Coles, A. Multiple Sclerosis. Lancet 2002; 359: 1221-31.

  5. Current MS therapies

  6. Prospective MS therapies

  7. Biogen Idec Valuation Traditional DCF Method:

  8. Valuation by industry multiples and recent acquisitions:

  9. DCF Valuation by drug

  10. Multiple valuations of BIOGEN-IDEC:

  11. APPENDICES

  12. The MS Pipeline: Phase III drugs

  13. The MS Pipeline: Phase I & II drugs

  14. Important features of licensing agreement:

  15. Post acquisition MS market share with synergies Post acquisition MS market share by firm 2006 MS market share by firm

  16. The following slides describe the details of the DCF valuation

More Related